The Thesis
DexCom is a medical device company that makes wearable sensors that track blood sugar levels in real time for people with diabetes. The company generated $4.66 billion in revenue in 2025, representing 15.6% growth as it expanded beyond its core base of insulin-dependent patients. The launch of the Stelo sensor for non-insulin users marks the structural shift that opens the technology to a market ten times larger than the one the company originally served.
What makes this work boils down to a few specific things.
We see DexCom as a multi-year compounder, driven by its expansion into the massive Type 2 diabetes market. The recent reset in growth expectations provides a reasonable entry point for investors who believe glucose monitoring will become a standard of care for all diabetics. The case remains strong as long as volume growth in the United States stays in the double digits and international expansion continues at its current pace.
Numbers at a Glance
What does it do?
DexCom is a growth business that earns money by selling disposable sensors and transmitters that monitor glucose levels 24 hours a day. A user applies a small sensor to their skin which sends sugar readings to a smartphone app every five minutes. The company primarily makes money through a recurring model where customers or their insurance providers pay for new sensors every 10 to 15 days. Because these sensors are essential for daily health management, customers typically stay on the product for years.
Where does revenue come from?
The vast majority of revenue comes from the sale of disposable sensors and hardware across the United States and international markets. US sales accounted for 70% of total revenue in the most recent quarter while international sales grew at a much faster 26% rate. Revenue is split between traditional medical distributors and direct sales to pharmacies, with the pharmacy channel becoming more important as the company moves toward consumer-led products like Stelo.
Revenue by Geography
Who are its customers?
DexCom serves millions of people with diabetes who require constant glucose data to manage their health and avoid dangerous blood sugar swings. While the company does not disclose its exact total user count in every report, its revenue growth suggests it is supporting over 2 million active users globally. The customer base is currently shifting from people with Type 1 diabetes to a much larger group of Type 2 diabetics who use long-acting insulin. With the launch of Stelo, the company is now targeting the estimated 25 million people in the US with Type 2 diabetes who do not use insulin at all.
What gives it staying power?
DexCom has staying power because of the high switching costs and regulatory hurdles that protect its place in a patient's daily routine. Once a patient and their doctor integrate DexCom data into a treatment plan, the friction of switching to a competitor is significant. The company also holds a vast library of patents on sensor accuracy and software integration.
Where is it headed?
The company is making its biggest strategic bet on the Stelo platform to capture the health-conscious consumer and non-insulin diabetic market. Management believes that by moving glucose monitoring into the over-the-counter category, they can create a new multi-billion dollar revenue stream. This shift requires a different marketing approach than the traditional medical sales model used for clinical devices.
Revenue growth remains healthy at 15% as the company successfully transitions to a higher-volume pharmacy model. This growth rate is supported by strong demand for the G7 sensor and a 26% jump in international sales. While the pace has slowed from the 20% range seen in previous years, the total dollar additions to the business are still climbing.
Free cash flow reached $1.08 billion in 2025, proving that the business is now a self-funding cash machine. This cash generation is driven by high gross margins of 61.8% and the fact that most customers are on recurring subscriptions. The company is now using this cash to expand manufacturing capacity in Ireland and Arizona rather than relying on debt.
The balance sheet is exceptionally strong with $2.42 billion in cash and a conservative debt level. With a debt-to-equity ratio of 0.47, the company has enough liquidity to fund its next five years of product development and potential acquisitions. This financial cushion provides stability as the company competes with larger rivals.
DexCom is a financially dominant business that has successfully moved past the heavy investment phase and into a period of high cash generation.
International growth is accelerating with a 26% increase this quarter as the G7 sensor launches in new global markets. The company is finding significant success in countries where government reimbursement for Type 2 patients has recently expanded. This provides a clear path for growth even if the US market becomes more competitive.
US revenue growth slowed to 11% this quarter as the company navigated changes in how its products are distributed. This drop from previous high-teen growth rates suggests that the legacy insulin-dependent market is maturing. Management must prove that the new Stelo product can quickly pick up the slack and return the domestic business to faster growth.
The continuous glucose monitoring market is roughly $12 billion today and is growing at approximately 12% annually as more Type 2 patients gain access to the technology. The market is on track to exceed $20 billion by 2030 as sensors move from being specialty medical tools to mainstream consumer health products. Pricing power is generally stable because these sensors are medically necessary for insulin users, though the shift toward the over-the-counter market is introducing more price competition. DexCom is a clear co-leader in this market, and its focus on being the premium, most-integrated sensor gives it a distinct advantage in the clinical segment.
The competitive dynamic is rationally structured as a duopoly between DexCom and Abbott(ABT), with both companies focusing on different segments of the market. While entry barriers for software are low, the manufacturing of reliable, clinical-grade chemical sensors is incredibly difficult and requires massive capital investment. The current environment allows for high margins because the market is expanding fast enough for both major players to win.
Abbott(ABT) is the most dangerous threat because its FreeStyle Libre platform is often priced lower and has broader reach in international primary care channels. Medtronic(MDT) competes by bundling sensors with its insulin pumps, creating a closed ecosystem that is hard for DexCom to enter. Senseonics(SENS) offers a niche alternative with an implantable device, but it lacks the ease of use and brand recognition of the market leaders. Abbott's ability to leverage its massive scale to undercut DexCom on price in the non-insulin market is the primary risk to watch.
DexCom is holding its ground by focusing on superior software integration and sensor accuracy. Its Q1 2026 results showed 15% revenue growth, which suggests it is keeping pace with the overall market. The company remains the gold standard for integrated diabetes management.
The primary source of protection for DexCom is high switching costs coupled with a deep portfolio of sensor technology patents. Once a patient is trained on the DexCom app and their data is shared with their doctor, moving to a competitor involves significant effort and clinical risk. These switching costs are proven by a high retention rate that has allowed revenue to grow consistently even as competition intensified.
The numbers confirm a durable edge, with a return on invested capital of 18% and gross margins holding steady above 61%. These metrics prove that DexCom does not have to compete solely on price to win customers. The combination of high margins and growing free cash flow suggests a moat that is based on structural product advantages rather than temporary market conditions.
The moat is strengthening as DexCom integrates its data into more third-party apps and devices like the Apple Watch and various insulin pumps. This ecosystem expansion makes DexCom sensors more indispensable to the user every year.
Delivered 15% revenue growth and 850 basis point margin expansion in Q1 2026.
Generated $1.08B in FCF while maintaining $2.42B in cash for expansion.
Management pay is heavily weighted toward long-term equity and operational performance targets.
Capital Allocation Track Record
Management has proven its ability to navigate a complex medical market while maintaining high profitability. By focusing on manufacturing efficiency and the expansion into the Type 2 market, leadership has positioned the company to remain a leader for the next decade. The recent promotion of Jake Leach to CEO ensures continuity in the company's technical and strategic direction as it moves into its next phase of growth.
© 2026 ClearThesis.ai · Report generated on May 26, 2026
This is an AI-generated analysis for informational purposes only and does not constitute financial advice. Data and analysis may not reflect recent developments if viewed significantly after the generation date. Always conduct your own due diligence before making any investment decisions.